Screening for Subclinical Coronary Microvascular Dysfunction: Clinical Evidence, Mechanisms, and Practical Approaches

Abstract

Coronary microvascular dysfunction (CMD) is increasingly recognized as a significant contributor to myocardial ischemia and adverse cardiovascular outcomes, especially in patients without obstructive coronary artery disease (CAD). Subclinical CMD often remains undiagnosed due to its elusive clinical presentation and limitations in standard screening modalities. Recent advances in noninvasive imaging and functional testing have improved the detection of subclinical CMD, facilitating earlier intervention and potentially altering disease trajectories. This review synthesizes the current evidence on the burden, mechanisms, risk factors, and clinical implications of subclinical CMD, highlights the evolving diagnostic landscape, and summarizes contemporary guideline recommendations for screening and management in clinical practice.

Introduction

Coronary microvascular dysfunction (CMD) refers to impaired regulation of blood flow within the coronary microcirculation, frequently occurring in the absence of significant epicardial coronary artery stenosis. CMD is an important yet underrecognized cause of myocardial ischemia and is associated with adverse cardiovascular outcomes. Subclinical CMD, characterized by the presence of microvascular impairment without overt clinical manifestations, poses unique diagnostic and therapeutic challenges. Given the growing awareness of CMD as a distinct entity, particularly in patients with angina and nonobstructive coronary arteries (ANOCA), understanding screening strategies for subclinical CMD has become increasingly relevant for clinicians and cardiology specialists.

Epidemiology / Disease Burden

Subclinical CMD is prevalent in diverse populations, affecting up to 50% of patients presenting with angina and unobstructed coronary arteries. Epidemiological studies demonstrate a higher prevalence in women, particularly postmenopausal women, and in individuals with cardiometabolic risk factors. Population-based data suggest that CMD is associated with an increased risk of major adverse cardiac events (MACE), heart failure with preserved ejection fraction (HFpEF), and all-cause mortality. The true burden of subclinical CMD is likely underestimated due to diagnostic limitations and underutilization of advanced functional testing in routine clinical care.

Pathophysiology

The pathogenesis of CMD involves a complex interplay between endothelial dysfunction, impaired smooth muscle relaxation, and structural remodeling of the microvascular network. Key mechanisms include reduced nitric oxide bioavailability, increased oxidative stress, and inflammation leading to microvascular spasm or rarefaction. Chronic exposure to cardiovascular risk factors accelerates these processes, resulting in impaired coronary flow reserve (CFR) and abnormal myocardial perfusion. Subclinical CMD is often an early manifestation of systemic vascular dysfunction, preceding overt atherosclerosis and myocardial injury.

Risk Factors

Risk factors for subclinical CMD largely mirror those of macrovascular CAD but also include unique contributors. Traditional risk factors such as hypertension, diabetes mellitus, dyslipidemia, obesity, and smoking are strongly associated with CMD. Nontraditional factors—such as autoimmune conditions, systemic inflammatory states, and hormonal imbalances—play a pivotal role, especially in women. Emerging evidence implicates genetic predispositions, microvascular rarefaction in metabolic syndrome, and chronic kidney disease in the development of CMD. Psychological stress and sedentary lifestyle may also contribute to microvascular dysfunction via neurohormonal and endothelial pathways.

Clinical Features

Subclinical CMD is typically asymptomatic but may present with subtle or atypical symptoms, such as exertional dyspnea, chest discomfort, or fatigue that is not explained by obstructive CAD. In some cases, patients may experience recurrent angina-like symptoms despite unremarkable coronary angiograms. The absence of overt ischemic changes on resting ECG or standard stress testing often leads to misdiagnosis or underdiagnosis. Awareness of CMD as a potential etiology in patients with unexplained symptoms and high-risk profiles is essential for timely identification and management.

Diagnosis

Screening for subclinical CMD requires a high index of suspicion, especially in patients with angina and nonobstructive coronary arteries. Noninvasive techniques such as cardiac positron emission tomography (PET), cardiac magnetic resonance imaging (CMR) with perfusion, and transthoracic Doppler echocardiography to assess coronary flow reserve are increasingly utilized. Invasive methods, including coronary functional testing with acetylcholine or adenosine during angiography, provide direct assessment of microvascular function but are less commonly performed due to procedural complexity. Biomarkers of endothelial dysfunction and microvascular injury are under investigation but are not yet routinely used. Recent guidelines emphasize the importance of integrating functional imaging with clinical assessment to improve diagnostic accuracy.

Treatment & Management

Management of subclinical CMD focuses on optimizing cardiovascular risk factors and improving microvascular function. First-line interventions include aggressive control of hypertension, diabetes, and dyslipidemia, alongside lifestyle modifications such as weight reduction, regular physical activity, and smoking cessation. Pharmacologic therapies, such as statins, ACE inhibitors, angiotensin receptor blockers, and beta-blockers, may confer benefit by improving endothelial function and reducing microvascular inflammation. In selected cases, antianginal agents (e.g., ranolazine, calcium channel blockers) and novel therapies targeting microvascular tone or inflammation are considered. Patient education and multidisciplinary care are integral to long-term management.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advances in both diagnostic and therapeutic approaches to subclinical CMD. Novel imaging techniques, including dynamic CT perfusion and hybrid PET/MRI, provide high-resolution assessment of microvascular perfusion. Pharmacologic agents targeting specific pathways, such as sodium-glucose cotransporter 2 (SGLT2) inhibitors and endothelin receptor antagonists, are under active investigation for their microvascular benefits. Ongoing clinical trials are evaluating the utility of endothelial progenitor cell therapies and gene-based interventions. Improved risk stratification algorithms using artificial intelligence and machine learning may further refine screening and therapeutic decision-making in the near future.

Guideline Recommendations

Contemporary guidelines from the American College of Cardiology (ACC), American Heart Association (AHA), and European Society of Cardiology (ESC) recognize CMD as a clinically significant entity warranting systematic evaluation in patients with persistent symptoms and nonobstructive CAD. Expert consensus supports the use of functional imaging to assess microvascular function in high-risk individuals. Guidelines advocate for aggressive risk factor modification, evidence-based pharmacotherapy, and consideration of referral to specialized centers for complex cases. Ongoing guideline updates emphasize the need for increased awareness and multidisciplinary approaches to improve outcomes in patients with subclinical CMD.

Conclusion

Subclinical coronary microvascular dysfunction represents an important frontier in cardiovascular medicine, with substantial implications for diagnosis, prognosis, and therapeutic intervention. Advances in screening modalities and understanding of pathophysiological mechanisms have enabled earlier identification of at-risk individuals, facilitating timely management and risk reduction. Clinicians should maintain a high index of suspicion in patients with angina and nonobstructive coronary arteries, and employ a combination of functional testing and risk factor assessment for optimal care. Continued research and innovation are essential to refine screening strategies, expand therapeutic options, and ultimately improve cardiovascular outcomes in this challenging patient population.